3% for sensitivity and 7.7% for the positive predictive value). For the total steatosis grade between preoperative Selleckchem Obeticholic Acid right biopsy versus intraoperative right and left biopsies, moderate agreement was seen as reflected by weighted kappa values of 0.44 and 0.40. The weighted kappa value between intraoperative right and left biopsies was 0.77, and thus indicating substantial agreement. Similar results were noted in macrovesicular and microvesicular steatosis subtypes. Multivariate analysis indicated that independent factors affecting the sampling variability of the total steatosis in preoperative and intraoperative biopsies, included greater systolic blood pressure (odds

ratio [OR], 1.01), body mass index (OR, 1.08) and serum alanine aminotransferase (OR,

1.02), and less high-density lipoprotein Selleck SCH727965 cholesterol (OR, 0.98; P <0.05 for all). Conclusions: Our data suggest that radiological studies were considerably limited for detecting donor hepatic steatosis in LDLT and that further substantial sampling variability exists between preoperative and intraoperative liver biopsies, according to the clinical and metabolic parameters. Therefore, preoperative and selective intraoperative liver biopsies should be performed to assess donor steatosis in LDLT. Disclosures: Han Chu Lee - Grant/Research Support: Medigen Biotechnology Co., Novartis, Roche, Bayer HealthCare, Bristol-Myers Squibb, INC research, Boehringer Ingelheim, Taiho Pharmaceutical Co., Yuhan Co. The following people have nothing to disclose: Mi-Jung Jun, Ju Hyun Shim, Kang Mo Kim, Young-Suk Lim, Dong Jin Suh Several noninvasive scoring systems had been developed in patients with NAFLD aimed at distinguishing between those with and without advanced liver fibrosis. They are the NAFLD fibrosis score (NFS), the aspartate aminotransferase (AST)/platelet ratio

index (APRI), the FIB-4 score, the NIKEI score, and the BARD score. Validation studies, however, had included small number of patients and most came from single centers. The AIM of our study was to perform a large, independent validation of those scoring systems. METHODS: A total of 672 patients with Casein kinase 1 NAFLD were included. Patients came from several institutions around the world and none of these patients had been included in the original prior studies that created the scoring systems. Fibrosis was staged on the scale 0 to 4 proposed by Kleiner et al. with stage 3 and 4 meaning adavnced fibrosis. The five scores mentioned above were calculated using the original published formulas. The same two cut-points described in the original publications were used to group patients; they were −1.455 and 0.676 for the NAFLD-FS; 0.5 and 1.5 for the APRI; 1.30 and 2.67 for the FIB-4; and 0. 。535 and 0.2294 for the NIKEI score. For the BARD score, a value >2 was used.